- Home
- APLM vs JZXN Comparison
APLM vs JZXN Comparison
Compare APLM & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- JZXN
- Stock Information
- Founded
- APLM 2016
- JZXN 2017
- Country
- APLM United States
- JZXN China
- Employees
- APLM N/A
- JZXN N/A
- Industry
- APLM Blank Checks
- JZXN Retail-Auto Dealers and Gas Stations
- Sector
- APLM Finance
- JZXN Consumer Discretionary
- Exchange
- APLM Nasdaq
- JZXN Nasdaq
- Market Cap
- APLM 15.6M
- JZXN 15.3M
- IPO Year
- APLM N/A
- JZXN 2021
- Fundamental
- Price
- APLM $0.14
- JZXN $1.31
- Analyst Decision
- APLM Strong Buy
- JZXN
- Analyst Count
- APLM 2
- JZXN 0
- Target Price
- APLM $4.25
- JZXN N/A
- AVG Volume (30 Days)
- APLM 876.0K
- JZXN 27.3K
- Earning Date
- APLM 08-14-2024
- JZXN 10-22-2024
- Dividend Yield
- APLM N/A
- JZXN N/A
- EPS Growth
- APLM N/A
- JZXN N/A
- EPS
- APLM N/A
- JZXN N/A
- Revenue
- APLM $2,101,000.00
- JZXN $7,597,423.00
- Revenue This Year
- APLM N/A
- JZXN N/A
- Revenue Next Year
- APLM N/A
- JZXN N/A
- P/E Ratio
- APLM N/A
- JZXN N/A
- Revenue Growth
- APLM 70.54
- JZXN 81.94
- 52 Week Low
- APLM $0.11
- JZXN $1.00
- 52 Week High
- APLM $2.06
- JZXN $67.60
- Technical
- Relative Strength Index (RSI)
- APLM 48.96
- JZXN 39.30
- Support Level
- APLM $0.13
- JZXN $1.36
- Resistance Level
- APLM $0.17
- JZXN $1.76
- Average True Range (ATR)
- APLM 0.01
- JZXN 0.17
- MACD
- APLM -0.00
- JZXN -0.01
- Stochastic Oscillator
- APLM 34.48
- JZXN 4.84
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.